Investor Presentation Q1 2023

26 Investor presentation First three months of 2023 Novo NordiskⓇ Novo Nordisk's core capabilities provide a competitive advantage to continue to defeat diabetes Engineering, formulating, developing and delivering protein-based treatments Efficient large-scale production of proteins Global commercial reach and leader in chronic disease care Deep disease understanding Today: Oral solutions to differentiate from competition Tomorrow: Expand oral platforms and transformational medicines via Novo Nordisk stem السمر balo Today: The world's largest producer of insulin and GLP-1 Tomorrow: Expand capacity and continue efficiency gains |.000 ② ५ Today: Global reach and industry leading GLP-1 portfolio Tomorrow: Continued rollout of portfolio and launch of new products ه D Today: Provide value and outcomes beyond HbA1c for diabetes Tomorrow: Normalise living with diabetes supported by digital solutions cell platform API: Active pharmaceutical ingredient; HbA₁: Refers to glycated haemoglobin, which is the average blood glucose (sugar) levels for the last three months

View entire presentation